Does early combination vs. Monotherapy improve clinical outcomes of clinically extremely vulnerable patients with COVID-19? Results from a retrospective propensity-weighted analysis

• Published in: European journal of medical research Vol. 29; no. 1; pp. 484 - 9
• Main Authors: Maria, Mazzitelli, Maraolo, Alberto Enrico, Cozzolino, Claudia, Sasset, Lolita, Ferrari, Anna, Basso, Monica, Vania, Eleonora, Bonadiman, Nicola, Scaglione, Vincenzo, Cattelan, Anna Maria
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 04.10.2024; BMC
• Subjects: Adenosine Monophosphate - analogs & derivatives; Adenosine Monophosphate - therapeutic use; Aged; Alanine - administration & dosage; Alanine - analogs & derivatives; Alanine - therapeutic use; Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; Combined treatment; COVID-19 - mortality; COVID-19 Drug Treatment; Drug Therapy, Combination; Early treatment; Female; Hospitalization - statistics & numerical data; Humans; Immunocompromised Host; Male; Middle Aged; Monoclonal antibodies; Monotherapy; Mortality; Propensity Score; Retrospective Studies; Ritonavir - therapeutic use; SARS-CoV-2; Severe immunocompromised patients; Treatment Outcome; SARS-CoV-2; Combined treatment; Severe immunocompromised patients; Early treatment; Monotherapy

The potential efficacy of early combination therapy, based on an antiviral plus a monoclonal antibody, for COVID-19 in severely immunocompromised patients is matter of debate. Our aim was to describe the impact on clinical outcomes of COVID-19 treatments in severely immunocompromised individuals, ev...